These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer. Shi L; Xu Y; Feng M Dig Dis Sci; 2023 Feb; 68(2):370-379. PubMed ID: 36575326 [TBL] [Abstract][Full Text] [Related]
68. Ezrin expression and cell survival regulation in colorectal cancer. Leiphrakpam PD; Rajput A; Mathiesen M; Agarwal E; Lazenby AJ; Are C; Brattain MG; Chowdhury S Cell Signal; 2014 May; 26(5):868-79. PubMed ID: 24462708 [TBL] [Abstract][Full Text] [Related]
69. An update on the use of immunotherapy in patients with colorectal cancer. Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649 [No Abstract] [Full Text] [Related]
70. Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. Nordgaard C; Doll S; Matos ALSA; Høeberg M; Kazi JU; Friis S; Stenvang J; Rönnstrand L; Mann M; Manuel Afonso Moreira J Mol Oncol; 2019 Dec; 13(12):2646-2662. PubMed ID: 31545548 [TBL] [Abstract][Full Text] [Related]
71. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. Kocoglu H; Velibeyoglu FM; Karaca M; Tural D World J Gastrointest Oncol; 2016 Jan; 8(1):1-7. PubMed ID: 26798432 [TBL] [Abstract][Full Text] [Related]
72. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Thomas J; Leal A; Overman MJ Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280 [TBL] [Abstract][Full Text] [Related]
73. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Solier S; Zhang YW; Ballestrero A; Pommier Y; Zoppoli G Curr Cancer Drug Targets; 2012 May; 12(4):356-71. PubMed ID: 22385513 [TBL] [Abstract][Full Text] [Related]
74. MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics. Yamamoto H; Mori M Adv Exp Med Biol; 2016; 937():239-47. PubMed ID: 27573904 [TBL] [Abstract][Full Text] [Related]
75. MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer. Pourdavoud P; Pakzad B; Mosallaei M; Saadatian Z; Esmaeilzadeh E; Alimolaie A; Shaygannejad A Mol Biol Rep; 2020 Dec; 47(12):9913-9920. PubMed ID: 33130965 [TBL] [Abstract][Full Text] [Related]
76. Monoclonal Antibodies in Cancer Therapy. Zahavi D; Weiner L Antibodies (Basel); 2020 Jul; 9(3):. PubMed ID: 32698317 [TBL] [Abstract][Full Text] [Related]
77. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Lee JJ; Chu E Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486 [TBL] [Abstract][Full Text] [Related]
78. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. Kumar A; Gautam V; Sandhu A; Rawat K; Sharma A; Saha L World J Gastrointest Surg; 2023 Apr; 15(4):495-519. PubMed ID: 37206081 [TBL] [Abstract][Full Text] [Related]
79. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276 [TBL] [Abstract][Full Text] [Related]